newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. , a clinical-stage pharmaceutical